Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could help diabetics shed pounds on top of existing meds

NCT ID NCT06851858

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 study tests an experimental drug called AZD6234, given as a weekly injection, for weight loss in adults with overweight or obesity and type 2 diabetes. Participants are already on a stable dose of a GLP-1 medication. The study will compare AZD6234 to a placebo over 26 weeks to see if it leads to greater weight loss. About 69 people will take part.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD6234 (weekly injection)
What this could lead to
If it works, this could offer a new option for weight loss in people with type 2 diabetes who are already on a GLP-1 medication.
What could go wrong
This is a small, early Phase 2 trial. It may not show enough benefit or could have side effects. Success in this study does not guarantee approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

69 people

The number who actually took part.

Started

Mar 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Be 18 to 75 years old at the time of signing the informed consent. 2. Diagnosed with type 2 diabetes ≥ 180 days before screening. 3. HbA1c value at screening of ≥ 6.0% (42 mmol/mol) and ≤ 10% (86 mmol/mol). 4. On a stable maintenance dose of an injectable GLP-1 RA. 5. At Screening, have a BMI ≥ 27 kg/m2 Exclusion Criteria: 1. Has received treatment with prescription or non-prescription medication for weight loss within the last 3 months prior to screening (other than a GLP-1 RA). 2. Self-reported weight change of \> 5 % in the 3 months prior to screening. 3. Diabetes mellitus that is not clearly type 2 diabetes. 4. Use of insulin therapy for T2DM 5. Previous or planned (within study period) bariatric surgery or fitting of a weight loss device (eg, gastric balloon or duodenal barrier) 6. Significant hepatobiliary disease (except for non-alcoholic steatohepatitis or nonalcoholic fatty liver disease without portal hypertension or cirrhosis) 8\. Impaired renal function defined as eGFR ≤ 45 mL/minute/1.73m2 at screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes type II are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endocrine system disorder Obesity obesity disorder type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes type II Endocrinology Obesity

Contacts and locations

Locations

  • Research Site

    Birmingham, Alabama, 35205, United States

  • Research Site

    Mobile, Alabama, 36608, United States

  • Research Site

    Doral, Florida, 33166, United States

  • Research Site

    Jacksonville, Florida, 32216, United States

  • Research Site

    Miami, Florida, 33135, United States

  • Research Site

    Miami, Florida, 33136, United States

  • Research Site

    Winter Park, Florida, 32789, United States

  • Research Site

    Canton, Georgia, 30114, United States

  • Research Site

    Fayetteville, Georgia, 30214, United States

  • Research Site

    Chicago, Illinois, 60640, United States

  • Research Site

    Oak Brook, Illinois, 60523, United States

  • Research Site

    Newton, Kansas, 67114, United States

  • Research Site

    Lexington, Kentucky, 40509, United States

  • Research Site

    Kansas City, Missouri, 64114, United States

  • Research Site

    Las Vegas, Nevada, 89119, United States

  • Research Site

    Norman, Oklahoma, 73069, United States

  • Research Site

    Knoxville, Tennessee, 37909, United States

  • Research Site

    San Antonio, Texas, 78229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.